Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The bigger picture w.r.t. the IBD drug ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(62)
•••
Comment by WalkOverTheStrton May 10, 2021 8:03am
138 Views
Post# 33163497

RE:The bigger picture w.r.t. the IBD drug ...

RE:The bigger picture w.r.t. the IBD drug ...MrMugsy biotechs with more than one shot on goal typically can recover from one of those drugs failing in preclinical. Down side is cash burn and dilution for raises.
Antibe experienced delays and believe a SAE based on a patient that lied about past liver issues (if memory serves) but none the less they are here. If Antibe resists offers until 346 or another drug is shown successful (if which is another high risk move) in human studies it could be until EOY 2022 before those results are issued (swag but based off past timelines of mgmt and if it is a phase 1 not lasting more than 60 days. I'd hope mgmt takes cash in hand for Oten and then builds out rest of pipeline. Oten can still fail and important to state if it did we SHs as well as Mgmt would be left with zero.  Cash is oxygen to a biotech/startup. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities